Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000226925 | SCV000284452 | benign | Neurofibromatosis, type 1 | 2024-09-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002311334 | SCV000662887 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2022-08-04 | criteria provided, single submitter | clinical testing | The c.4000G>A (p.E1334K) alteration is located in exon 30 (coding exon 30) of the NF1 gene. This alteration results from a G to A substitution at nucleotide position 4000, causing the glutamic acid (E) at amino acid position 1334 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000681004 | SCV000808453 | uncertain significance | not provided | 2022-06-30 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25486365, 22807134) |
Genome Diagnostics Laboratory, |
RCV000226925 | SCV001479271 | uncertain significance | Neurofibromatosis, type 1 | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000569305 | SCV002527548 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-09 | criteria provided, single submitter | curation | |
Genome- |
RCV000226925 | SCV002560359 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004567716 | SCV005052187 | uncertain significance | Juvenile myelomonocytic leukemia | 2024-03-18 | criteria provided, single submitter | clinical testing |